Laboratorio Reig (RJF) | Financial Analysis & Statements
Laboratorio Reig Jofre S.A. Mid-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
163.7M
Gross Profit
99.8M
61.00%
Operating Income
4.1M
2.53%
Net Income
3.5M
2.13%
EPS (Diluted)
€0.04
Balance Sheet Metrics
Total Assets
394.7M
Total Liabilities
174.2M
Shareholders Equity
220.4M
Debt to Equity
0.79
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Laboratorio Reig Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 331.1M | 338.9M | 316.1M | 271.2M | 236.2M |
| Cost of Goods Sold | 135.3M | 143.2M | 137.1M | 113.8M | 91.3M |
| Gross Profit | 195.8M | 195.7M | 179.0M | 157.3M | 145.0M |
| Gross Margin % | 59.2% | 57.7% | 56.6% | 58.0% | 61.4% |
| Operating Expenses | |||||
| Research & Development | 13.0M | 6.0M | 5.4M | 4.5M | 4.9M |
| Selling, General & Administrative | 28.5M | 26.5M | 22.7M | 20.0M | 18.2M |
| Other Operating Expenses | 34.9M | 37.2M | 39.3M | 32.3M | 30.1M |
| Total Operating Expenses | 76.4M | 69.7M | 67.4M | 56.8M | 53.2M |
| Operating Income | 6.8M | 15.1M | 12.4M | 9.2M | 9.4M |
| Operating Margin % | 2.1% | 4.4% | 3.9% | 3.4% | 4.0% |
| Non-Operating Items | |||||
| Interest Income | 5.0M | 287.0K | 63.0K | 101.0K | 50.0K |
| Interest Expense | 1.4M | 1.0M | 745.0K | 687.0K | 679.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 6.3M | 11.8M | 10.5M | 8.8M | 5.8M |
| Income Tax | 1.3M | 1.4M | 1.1M | 658.0K | 713.0K |
| Effective Tax Rate % | 20.9% | 11.5% | 10.5% | 7.5% | 12.3% |
| Net Income | 5.0M | 10.5M | 9.4M | 8.1M | 5.1M |
| Net Margin % | 1.5% | 3.1% | 3.0% | 3.0% | 2.2% |
| Key Metrics | |||||
| EBITDA | 36.0M | 37.7M | 36.2M | 31.7M | 27.0M |
| EPS (Basic) | €0.06 | €0.13 | €0.12 | €0.10 | €0.07 |
| EPS (Diluted) | €0.06 | €0.13 | €0.12 | €0.10 | €0.07 |
| Basic Shares Outstanding | 81389162 | 80057011 | 78804046 | 78881854 | 77854054 |
| Diluted Shares Outstanding | 81389162 | 80057011 | 78804046 | 78881854 | 77854054 |
Income Statement Trend
Laboratorio Reig Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 10.5M | 10.5M | 5.5M | 6.5M | 5.1M |
| Short-term Investments | 6.3M | 5.6M | 830.0K | 298.0K | 973.0K |
| Accounts Receivable | 67.2M | 57.2M | 56.9M | 52.2M | 47.2M |
| Inventory | 61.5M | 63.7M | 61.7M | 48.1M | 47.6M |
| Other Current Assets | 4.2M | 1.6M | 2.0M | 2.1M | 4.4M |
| Total Current Assets | 155.4M | 149.7M | 132.6M | 112.3M | 108.8M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 9.6M | 8.8M | 8.8M | 8.3M | 7.8M |
| Goodwill | 122.6M | 108.9M | 119.0M | 128.8M | 137.4M |
| Intangible Assets | 69.6M | 55.3M | 63.1M | 70.9M | 77.7M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 239.3M | 195.2M | 198.0M | 208.9M | 216.1M |
| Total Assets | 394.7M | 344.9M | 330.5M | 321.2M | 325.0M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 36.3M | 35.1M | 41.5M | 36.1M | 35.1M |
| Short-term Debt | 33.0M | 21.4M | 30.1M | 23.8M | 18.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | 268.0K | 2.1M |
| Total Current Liabilities | 101.1M | 82.1M | 90.2M | 75.6M | 74.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 58.5M | 37.1M | 23.4M | 37.4M | 49.1M |
| Deferred Tax Liabilities | 2.3M | 2.4M | 2.6M | 2.8M | 3.1M |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 73.1M | 48.8M | 36.1M | 51.0M | 61.5M |
| Total Liabilities | 174.2M | 130.9M | 126.3M | 126.6M | 136.5M |
| Equity | |||||
| Common Stock | 41.1M | 40.4M | 39.8M | 39.2M | 38.7M |
| Retained Earnings | 5.0M | 10.4M | 9.4M | 8.1M | 5.1M |
| Treasury Stock | 2.8M | 2.9M | 2.8M | 2.8M | 2.4M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 220.4M | 214.0M | 204.3M | 194.6M | 188.5M |
| Key Metrics | |||||
| Total Debt | 91.5M | 58.5M | 53.5M | 61.2M | 67.4M |
| Working Capital | 54.3M | 67.6M | 42.4M | 36.7M | 33.9M |
Balance Sheet Composition
Laboratorio Reig Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 6.3M | 11.8M | 10.5M | 8.8M | 5.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -4.4M | -3.3M | -18.4M | -4.1M | -8.9M |
| Operating Cash Flow | -14.6M | 7.6M | -8.9M | -4.4M | -6.2M |
| Investing Activities | |||||
| Capital Expenditures | -14.2M | -20.3M | -12.5M | -10.8M | -19.1M |
| Acquisitions | - | -6.6M | 0 | -2.0M | -15.0M |
| Investment Purchases | -678.0K | -5.0M | -336.0K | -184.0K | -282.0K |
| Investment Sales | 116.0K | 391.0K | 226.0K | 707.0K | 234.0K |
| Investing Cash Flow | -14.8M | -31.4M | -12.6M | -12.3M | -34.2M |
| Financing Activities | |||||
| Share Repurchases | - | -3.0K | -20.0K | -363.0K | -753.0K |
| Dividends Paid | -32.0K | -25.0K | -41.0K | -53.0K | -55.0K |
| Debt Issuance | 32.5M | 32.9M | 10.2M | 13.8M | 22.9M |
| Debt Repayment | -23.9M | -28.4M | -18.0M | -16.8M | -15.2M |
| Financing Cash Flow | 16.3M | 5.6M | -7.2M | -2.0M | 13.7M |
| Free Cash Flow | -16.8M | 10.6M | 6.3M | 4.7M | -5.3M |
| Net Change in Cash | -13.1M | -18.3M | -28.6M | -18.7M | -26.7M |
Cash Flow Trend
Laboratorio Reig Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
45.17
Forward P/E
22.58
Price to Book
1.01
Price to Sales
0.66
PEG Ratio
-1.36
Profitability Ratios
Profit Margin
1.49%
Operating Margin
0.22%
Return on Equity
2.30%
Return on Assets
0.96%
Financial Health
Current Ratio
1.54
Debt to Equity
42.21
Beta
0.90
Per Share Data
EPS (TTM)
€0.06
Book Value per Share
€2.68
Revenue per Share
€4.14
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| RJF | 220.6M | 45.17 | 1.01 | 2.30% | 1.49% | 42.21 |
| Laboratorios | 4.3B | 36.12 | 6.59 | 22.33% | 18.89% | 18.04 |
| Almirall S.A | 2.8B | 58.64 | 1.86 | 3.10% | 4.14% | 23.30 |
| Faes Farma S.A | 1.5B | 19.60 | 2.05 | 10.82% | 12.70% | 58.11 |
| Labiana Health S.A | 49.2M | 42.50 | 7.81 | 23.11% | 1.26% | 998.21 |
| Grifols, S.A | 6.1B | 15.58 | 1.19 | 6.17% | 5.34% | 126.83 |
Financial data is updated regularly. All figures are in the company's reporting currency.





